RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Abionyx Pharma ROA 2024

Abionyx Pharma ROA

-0.24

Abionyx Pharma Dividend yield

Ticker

ABNX.PA

ISIN

FR0012616852

WKN

A14QR9

In 2024, Abionyx Pharma's return on assets (ROA) was -0.24, a -10.78% increase from the -0.27 ROA in the previous year.

Abionyx Pharma Aktienanalyse

What does Abionyx Pharma do?

Abionyx Pharma SA is a biotechnology company based in France that specializes in the development and commercialization of innovative therapeutic approaches for rare diseases. The company was founded in 2000 by a group of scientists and pharmaceutical experts and has since become a leading company in the industry. The business model of Abionyx Pharma is based on the discovery and development of drugs for rare diseases. The company focuses in particular on diseases for which there are still no or only inadequate therapies. With this focus, Abionyx Pharma takes advantage of orphan drug designations and other incentive programs offered by governments and authorities around the world. These programs are intended to provide incentives for the research and development of drugs for rare diseases. Abionyx Pharma has a wide range of products in various stages of development. These include therapeutics for musculoskeletal diseases, neural disorders, and chronic inflammation. The company also has a portfolio of compounds and drugs that can be used as a platform for the development of drugs for other diseases. One of Abionyx Pharma's key products is ONO-8455, a treatment package for osteoarthritis. This is a common joint disease caused by progressive cartilage wear. ONO-8455 has the potential to be a very important therapy option for the disease and could potentially become a blockbuster drug. Another important product from Abionyx Pharma is ABX464. This is a topical therapy for the treatment of hemorrhoid inflammation. ABX464 has been tested in clinical trials and has shown promising results in terms of its effectiveness in treating hemorrhoids. Abionyx Pharma also has other projects in the pipeline, including a therapy for Fabry disease. Fabry disease is a very rare genetic disorder that affects the metabolism of lipids and other important molecules in the body. Abionyx Pharma is developing a therapy based on a novel technology that acts through DNA methylation. To achieve its business goals, Abionyx Pharma works closely with scientific and clinical partners. It also forms strategic alliances with other pharmaceutical companies to market its products globally and gain a significant market share. Overall, Abionyx Pharma is an attractive company for investors looking for a biotechnology company specializing in the development and commercialization of drugs for rare diseases. The company has a strong portfolio of products in various stages of development and has already presented promising results. With its close collaboration with partners and strategic alliances, it is able to market its products globally and remain a strong competitor in the industry. Abionyx Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Abionyx Pharma's Return on Assets (ROA)

Abionyx Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Abionyx Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Abionyx Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Abionyx Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Abionyx Pharma Stock

What is the Return on Assets (ROA) of Abionyx Pharma this year?

The Return on Assets (ROA) of Abionyx Pharma is -0.24 undefined this year.

What was the ROA of Abionyx Pharma compared to the previous year?

The ROA of Abionyx Pharma has increased by -10.78% compared to the previous year.

What consequences do high ROA have for investors of Abionyx Pharma?

A high ROA is advantageous for investors of Abionyx Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Abionyx Pharma?

A low ROA can be unfavorable for investors of Abionyx Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Abionyx Pharma affect the company?

An increase in ROA of Abionyx Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Abionyx Pharma impact the company?

A reduction in the ROA of Abionyx Pharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Abionyx Pharma?

Some factors that can influence the ROA of Abionyx Pharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Abionyx Pharma important for investors?

The ROA of Abionyx Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Abionyx Pharma take to improve ROA?

To improve ROA, Abionyx Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Abionyx Pharma pay?

Over the past 12 months, Abionyx Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abionyx Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Abionyx Pharma?

The current dividend yield of Abionyx Pharma is .

When does Abionyx Pharma pay dividends?

Abionyx Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abionyx Pharma?

Abionyx Pharma paid dividends every year for the past 0 years.

What is the dividend of Abionyx Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abionyx Pharma located?

Abionyx Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abionyx Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abionyx Pharma from 6/1/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did Abionyx Pharma pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of Abionyx Pharma in the year 2023?

In the year 2023, Abionyx Pharma distributed 0 EUR as dividends.

In which currency does Abionyx Pharma pay out the dividend?

The dividends of Abionyx Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abionyx Pharma

Our stock analysis for Abionyx Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abionyx Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.